RELATED CONTENT
NEWS
- Orexigen expects 2nd half Contrave resubmission; Arena seeks European, Chinese partners
- Arena/Eisai anti-obesity drug wins US FDA nod; CVOT postapproval, no REMS
- Belviq enters Asian arena as Ildong gains Korean rights
- US payers begin to weigh up benefits of obesity drugs on wider health costs

